Peter D. Eisenberg

Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial

Christina A. Meyers, Jennifer A. Smith, Andrea Bezjak et al. · Journal of Clinical Oncology · 2003 · 585 citations · Full text

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Harold J. Burstein, Anthony Elias, Hope S. Rugo et al. · Journal of Clinical Oncology · 2008 · 483 citations · Full text

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

David Warr, Paul J. Hesketh, Richard J. Gralla et al. · Journal of Clinical Oncology · 2005 · 464 citations

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg et al. · Journal of Clinical Oncology · 2012 · 455 citations · Full text

Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT₃ receptor antagonist

Peter D. Eisenberg, Jazmin Figueroa‐Vadillo, Rosalio Zamora et al. · Cancer · 2003 · 404 citations · Full text